about
Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience.Preoperative imaging in renal cell cancer.PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium.Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.Chemotherapy of premalignant lesions: new insights.European Study of Radical Prostatectomy: time trends in Europe, 1993-2005.Summary of the Standards, Options and Recommendations for the management of patients with nonmetastatic prostate cancer (2001).Is there any evidence of superiority between retropubic, laparoscopic or robot-assisted radical prostatectomy?The use of estramustine phosphate in the modern management of advanced prostate cancer.Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy.Prostate cancer characteristics in a multiracial community.Early detection of prostate cancer in men with prostatism and intermediate prostate-specific antigen levels.Is seminal vesicle ablation mandatory for all patients undergoing radical prostatectomy? A multivariate analysis on 1283 patients.Can Power Doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy?The 20-core prostate biopsy protocol--a new gold standard?Update on urology--prostatic cancer. 2--Diagnosis and assessment of prostatic cancer.Variations in arterial blood supply and the risk of hemorrhage during percutaneous treatment of lesions of the pelviureteral junction obstruction: report of a case of testicular artery arising from an inferior polar renal artery.The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study.[Transvaginal repair of genital prolapse using the Prolift technique: a prospective study].[Update on the use of estramustin in metastatic prostate cancer].[CCAFU Recommendations 2013: Prostate cancer].Frequency of renal phosphate leak among patients with calcium nephrolithiasis.Words of wisdom: re: transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer.Nephron-sparing surgery for renal tumors measuring more than 7 cm: morbidity, and functional and oncological outcomes.[Practice uptake in France before and after the 2010 French guidelines on kidney cancer].[Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma.The learning curve of transrectal ultrasound-guided prostate biopsies: implications for training programs.Stage pT0 after radical prostatectomy with previous positive biopsy sets: a multicenter study.Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.Prostate saturation biopsy in the reevaluation of microfocal prostate cancer.[Urethral strictures treated with excision and primary anastomosis: Impact of etiology on care pathways and management].Repeat mid-urethral sling for recurrent female stress urinary incontinence.[Introduction of the photoselective vaporization of the prostate in an outpatient setting: Outcomes after the first 100 cases].[Scrotal trauma: management strategy]18F-Choline PET/CT and Prostate MRI for Staging Patients With Biochemical Relapse After Irradiation for Prostate Cancer.Subcutaneous pyelovesical bypass as replacement for standard percutaneous nephrostomy for palliative urinary diversion: prospective evaluation of patient's quality of life.[Neoadjuvant chemotherapy in muscular invasive bladder cancer: Complications and consequences with cystectomy].Clearance of free and total serum PSA after prostatic surgery.
P50
Q33317042-F3B3E6CF-AEF2-4069-8115-AA1BCD77B4D2Q34549825-8E136E34-C947-4684-990B-DEA8D0A9B966Q35036558-A1FE8A7C-CD08-4345-AF85-B0C0D4F1322DQ35157636-0040FC6A-A9D7-4D85-AD35-4B60E5F25E45Q36120837-7A4F45C6-9F95-44C7-9748-AB4901C72E95Q36861739-52DB7DB6-3920-4F03-AB31-F7F97EF44DE2Q36861743-4B723203-DCA6-443C-8C3F-4A1E10203C1AQ37365212-F5C70091-4458-4CAF-9416-FB8F26A1CB42Q37873972-7B4B4502-D7A4-40B0-92C6-A37B2026F415Q37901085-A4C2FF73-75C4-40F4-8275-FA390D4A123BQ39370414-9B1C0755-8DBC-459D-989A-F357D870627AQ39386509-53923A8E-1A4B-4240-9F6F-70F65AA7CF92Q39422696-46793075-DBAC-406D-B244-DE03212EC9CEQ39686755-60C9911D-2A0A-42BA-9C3A-F93A582CE828Q39694509-38C891F9-CD60-47B7-8068-913DFD370D2BQ39825591-EE6585B7-497B-410D-BBD6-A0C9CC4DEDAAQ40403855-3C4BC555-D8F6-4D05-AE9E-332AB4676F5CQ40725109-BD330284-1B70-4478-AAC0-F65AA4166B1EQ41366945-E5131F84-92FA-4B6D-B6FD-5BB64A39E2B8Q42910721-D4316211-65C0-44B3-BC9C-5C4DE2DF4D4EQ43177833-DB5948A4-D9F7-47FA-88B9-6A7361777CDBQ43440505-DD590D10-C4AC-4052-8401-3B7EDCB74B6AQ43651247-EDBBA511-4078-435F-B02F-6F7637D96EB4Q43695892-72431CE0-A0F5-4148-845F-782EE3A85279Q43746583-0D443405-C08D-44C6-B1EE-28A44F024D65Q45150572-455F36A6-8CA8-4A87-B5F8-6A21D8CFEB1AQ45844516-4EB6DADF-D53E-4815-ACCF-0E8BE137BEBEQ46040397-B7F1B091-B476-48F4-B346-A2088A883677Q46070390-C93AC3C6-CD27-49C0-B03F-1DFED33ABD08Q46123684-D147B315-DA27-47C2-BDEE-21041A9D2747Q47771329-46090F43-A697-4093-80DD-94CCCD6650DBQ48674132-8F31F592-5B85-42A9-8A5D-B7FF1A73BB71Q50862542-D3BF6396-7C41-407E-B42A-72A011023A3AQ51310965-562E69AD-90BE-4F05-A973-FA647FF72DE1Q51755578-C6874E6A-F078-4E3E-8347-D615AC1629BEQ52570943-6DE91957-0D32-49A8-A545-958189B60069Q52992142-3EBA7D64-CB3F-4993-A50D-F17DBAE33DD1Q53202809-E9124F35-FFBB-4843-ADD9-82A9D56FE9DBQ53488846-820E357C-A365-450C-80BD-8189DDAE1F20Q53955992-B44ADCEF-CDCE-42C8-BA39-7F0D665BFEA5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vincent Ravery
@ast
Vincent Ravery
@en
Vincent Ravery
@es
Vincent Ravery
@nl
Vincent Ravery
@sl
type
label
Vincent Ravery
@ast
Vincent Ravery
@en
Vincent Ravery
@es
Vincent Ravery
@nl
Vincent Ravery
@sl
prefLabel
Vincent Ravery
@ast
Vincent Ravery
@en
Vincent Ravery
@es
Vincent Ravery
@nl
Vincent Ravery
@sl
P106
P1153
7006569323
P21
P31
P496
0000-0001-6189-7243